When Graves’ disease reaches the eyes: The treatment that changed thyroid eye disease

The eyes can become their own thyroid problem

Graves’ disease is best known for causing hyperthyroidism, but the immune process can also affect orbital tissues. Swelling and tissue expansion behind the eye can produce redness, pain, pressure, double vision, and proptosis.

That means a normal TSH after Graves’ treatment does not automatically mean the eye disease is finished. The endocrine problem and the orbital problem are connected but not identical.

The pivotal trial produced an unusually visible effect

In the phase 3 OPTIC trial, 83 adults with active thyroid eye disease received teprotumumab or placebo. At week 24, 83% of patients receiving teprotumumab had at least a 2 mm reduction in proptosis compared with 10% receiving placebo.

Overall response, inflammation scores, double vision, and thyroid eye disease quality of life also favored teprotumumab. The treatment targets the insulin-like growth factor I receptor (IGF-1R), which is implicated in the disease process.

A pair of sunglasses can reduce outdoor light discomfort, but they do not treat orbital inflammation.

Eye symptoms deserve their own follow-up

Thyroid eye disease severity ranges from irritation and appearance changes to corneal exposure or optic nerve compression. Smoking is a major modifiable risk factor for worse disease.

Treatment depends on activity, severity, duration, thyroid status, and individual risk. Options can include lubrication, anti-inflammatory treatment, targeted therapy, radiation in selected cases, and surgery.

A soft sleep mask may be comfortable for some people, but avoid anything that presses on prominent or irritated eyes. A symptom notebook can document double vision, pain, redness, and day-to-day changes.

Targeted treatment has trade-offs

Teprotumumab is not a cosmetic infusion. Reported adverse effects include hyperglycemia, muscle spasms, hearing-related problems, and other treatment risks that require clinical monitoring.

Later real-world experience has made hearing assessment an especially important part of the conversation. The benefit-risk decision belongs with clinicians experienced in thyroid eye disease.

A water bottle supports ordinary hydration during treatment but should not be presented as an eye-disease intervention.

Thyroid control still matters to the eyes

Although orbital disease has its own course, uncontrolled hyperthyroidism and unstable thyroid status can complicate management. The goal is coordinated care rather than choosing between an endocrinologist and an eye specialist.

People with thyroid eye disease often benefit from clinicians who routinely manage the condition because treatment decisions can depend on both endocrine and ophthalmic details.

The Livium recipe

Tool. Photograph visible eye changes periodically if the care team finds that useful.

Behavior. Keep thyroid control, smoking cessation, and ophthalmic follow-up in the same plan.

Threshold. New vision loss, color desaturation, severe pain, or inability to close the eye requires prompt evaluation.

Source: Douglas et al., New England Journal of Medicine, 2020.

The symptoms can affect everyday function

Double vision can make driving, reading, stairs, and screen work difficult. Proptosis can expose the surface of the eye and change appearance in ways that affect quality of life well beyond the laboratory diagnosis.

Those functional outcomes are why thyroid eye disease research measures more than inflammation. The goal is not merely a quieter immune marker. It is better vision, comfort, appearance, and daily function.

There is also a prevention side

Smoking cessation is one of the most important modifiable steps for people with Graves’ disease because smoking is associated with greater risk and severity of thyroid eye disease. Avoiding smoke exposure belongs beside medication and eye care, not in a separate wellness category.

Selenium has been studied in mild thyroid eye disease in selenium-deficient regions, but supplements should not be generalized to every patient or taken in excessive doses.

Plan of action

• Keep thyroid decisions tied to repeatable laboratory and clinical evidence.
• Track changes over time instead of reacting to one isolated result.
• Tell clinicians about prescriptions, supplements, and major medication changes.
• Use urgent care for severe or rapidly changing symptoms rather than self-adjusting thyroid treatment.